An Association Between Liraglutide Treatment and Reduction in Excessive Daytime Sleepiness in Obese Subjects with Type 2 Diabetes

A study was conducted to see whether liraglutide helped with improving excessive daytime sleepiness for those with Type II diabetes who were also obese. This included 158 obese adults with a body mass of over 30kg/m2 and Type II diabetes who had begun liraglutide therapy at the start of the study. A significant amount of data was collected, including data from the Epworth Sleeping Scale (ESS), anthropometric parameters, glucose-control, and metabolic parameters. This data was collected at baseline and at both one month and three months after baseline.

The results showed major reductions in ESS score with the study participants at both months 1 and 3 (-1.3±2 p <0.001 and -1.5 ± 3.0 p<-.001, respectively). Significant reductions were also seen after 3 months in body weight, BMI, waist and neck circumferences, HbA1c, mean blood glucose, fasting blood glucose, triglycerides, and total cholesterol levels.

Overall, 3 months of liraglutide treatment proved effective in reducing excessive daytime sleepiness in obese participants with Type II diabetes. More research is required to see if liraglutide could improve other abnormal sleep pattern disorders and obstructive sleep aponea. I am wondering if liraglutide does one day prove to be effective in improving these disorders, would it be able to be indicated for patients without diabetes or obesity but with sleep disorders?

BMC Endocr Disord. 2015 Dec 4;15:78